Estrogen receptors and their downstream targets in cancer

Archives of Histology and Cytology

Volumn 67, Issue 5, 2004, Pages 435-442

  Kazuhiro, Ikeda ^a   Satoshi, Inoue ^a,b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTROGEN; ESTROGEN RECEPTOR; ISOPROTEIN; PHOSPHOTRANSFERASE; PROTEIN 14 3 3; PROTEIN 14 3 3SIGMA; REGULATOR PROTEIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CORRELATION ANALYSIS; EFP GENE; ESTROGEN RESPONSIVE ELEMENT; GENE; GENE EXPRESSION; GENE ISOLATION; GENE TARGETING; HORMONAL THERAPY; HORMONE ACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGAND BINDING; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; TARGET CELL; UTERUS;

14-3-3 PROTEINS; ANIMALS; BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR MODULATORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; MODELS, BIOLOGICAL; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION, GENETIC; UBIQUITIN-PROTEIN LIGASES;

EID: 15844388060     PISSN: 09149465     EISSN: None     Source Type: Journal    
DOI: 10.1679/aohc.67.435     Document Type: Review

References (42)

1. Ali S, Combos RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2: 101-112 (2002).
2. The ATAC Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359: 2131-2139 (2002).
3. Buzdar AU, Hortobagyi GN: Aromatase inhibitors in the treatment of breast cancer, In: Breast cancer management (Nabholtz JM, Tonkin K, Aapro MS, Buzdar AU, ed), Martin Dunitz Ltd., London, 2000 (p. 171-180).
4. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B: 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature 401: 616-620 (1999).
5. Chen D, Riedl T, Washbrook E, Pace PE, Coombes RC, Egly JM, Ali S: Activation of estrogen receptor α by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Mol Cell 6: 127-137 (2000).
6. Clarke R, Skaar T, Baumann K, Leonessa F, James M, Lippman J, Thompson EW, Freter C, Brunner N: Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression. Breast Cancer Res Treat 31: 237-248 (1994).
7. Clemons M, Goss P: Estrogen and the risk of breast cancer. N Engl J Med 344: 276-285 (2001).
8. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467 (1998).
9. Fisher ER, Osborne CK, McGuire WL, Redmond C, Knight WA, Fisher B, Bannayan G, Walder A, Jacobson AA, Queen DM, Bennett DE, Ford HC: Correlation of primary breast cancer histopathology and estrogen receptor content. Breast Cancer Res Treat 1: 37-41 (1981).
10. Foster JS, Henley DC, Bukovsky A, Seth P, Wimalasena J: Multifaceted regulation of cell cycle progression by estrogen: Regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function. Mol Cell Biol 21: 794-810 (2001).
11. Fujimura T, Takahashi S, Urano T, Ogawa S, Ouchi Y, Kitamura T, Muramatsu M, Inoue S: Differential expression of estrogen receptor β (ERβ) and its C-terminal truncated splice variant ERβcx as prognostic predictors in human prostatic cancer. Biochem Biophys Res Commun 289: 692-699 (2001).
12. Glass CK, Rosenfeld MG: The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14: 121-141 (2000).
13. Hayashi S-I, Imai K, Suga K, Kurihara T, Higashi Y, Nakachi K: Two promoters in expression of estrogen receptor messenger RNA in human breast cancer. Carcinogenesis 18: 459-464 (1997).
14. Holinka CF, Hata H, Kuramoto H, Gurpide E: Responses to estradiol in a human endometrial adenocarcinoma cell line (Ishikawa). J Steroid Biochem 24: 85-89 (1986).
15. Howell A: New antiestrogens: modulators of estrogen action. In: Breast cancer management (Nabholtz JM, Tonkin K, Aapro MS, Buzdar AU, ed), Martin Dunitz Ltd., London, 2000 (p. 143-169).
16. Ikeda K, Orimo A, Higashi Y, Muramatsu M, Inoue S: Efp as a primary estrogen-responsive gene in human breast cancer. FEBS Lett 472: 9-13 (2000).
17. Ikeda K, Ogawa S, Tsukui T, Horie-Inoue K, Ouchi Y, Kato S, Muramatsu M, Inoue S: Protein phosphatase 5 is a negative regulator of estrogen receptor-mediated transcription. Mol Endocrinol 18: 1131-1143 (2004).
18. Inoue S, Kondo S, Hashimoto M, Kondo T, Muramatsu M; Isolation of estrogen receptor-binding sites in human genomic DNA. Nucleic Acids Res 19: 4091-4096 (1991).
19. Inoue S, Orimo A, Hosoi T, Kondo S, Toyoshima H, Kondo T, Ikegami A, Ouchi Y, Orimo H, Muramatsu M: Genomic binding-site cloning reveals an estrogen-responsive gene that encodes a RING finger protein. Proc Natl Acad Sci USA 90: 11117-11121 (1993).
20. Inoue S, Kondo S, Muramatsu M: Identification of target genes for a transcription factor by genomic binding site (GBS) cloning. In: Transcription factors - A practical approach, 2nd ed (Latchman DS, ed), Oxford University Press, New York, 1999 (p.165-178).
21. Jensen K, Shiels C, Freemont PS: PML protein isoforms and the RBCC/TRIM motif. Oncogene 20: 7223-7233 (2001).
22. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491-1494 (1995).
23. Leygue E, Dotzlaw H, Watson PH, Murphy LC: Expression of estrogen receptor β1, β2, and β5 messenger RNAs in human breast tissue. Cancer Res 59: 1175-1179 (1999).
24. Millis RR: Correlation of hormone receptors with pathological features in human breast cancer. Cancer 46: 2869-2871 (1980).
25. Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW: Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA 96: 1858-1862 (1999).
26. Nuclear Receptors Committee: A unified nomenclature system for the nuclear receptor subfamily. Cell 97: 1-20 (1999).
27. Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, Muramatsu M: Molecular cloning and characterization of human estrogen receptor βcx: a potential inhibitor of estrogen action in human. Nucleic Acids Res 26: 3505-3512 (1998).
28. Omoto Y, Kobayashi S, Inoue S, Ogawa S, Toyama T, Yamashita H, Muramatsu M, Gustafsson J-Å, Iwase H: Evaluation of oestrogen receptor β wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur J Cancer 38: 380-386 (2002).
29. Orimo A, Inoue S, Ikeda K, Noji S, Muramatsu M: Molecular cloning, structure, and expression of mouse estrogen-responsive finger protein Efp. Co-localization with estrogen receptor mRNA in target organs, J Biol Chem 270: 24406-24413 (1995).
30. Orimo A, Inoue S, Minowa O, Tominaga N, Tomioka Y, Sato M, Kuno J, Hiroi H, Shimizu Y, Suzuki M, Noda T, Muramatsu M: Underdeveloped uterus and reduced estrogen responsiveness in mice with disruption of the estrogen-responsive finger protein gene, which is a direct target of estrogen receptor α. Proc Natl Acad Sci USA 96: 12027-12032 (1999).
31. Pickart CM: Mechanisms underlying ubiquitination. Ann Rev Biochem 70: 503-533 (2001).
32. Rose PG: Endometrial carcinoma. N Engl J Med 335: 640-649 (1996).
33. Ruffner H, Joazeiro CA, Hemmati D, Hunter T, Verma IM: Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci USA 98: 5134-5139 (2001).
34. Saji S, Omoto Y, Shimizu C, Warner M, Hayashi Y, Horiguchi S, Watanabe T, Hayashi S, Gustafsson JA, Toi M: Expression of estrogen receptor (ER) βcx protein in ERα-positive breast cancer: specific correlation with progesterone receptor. Cancer Res 62: 4849-4853 (2002).
35. Sasano H, Suzuki T, Matsuzaki Y, Fukaya T, Endoh M, Nagura H, Kimura M: Messenger ribonucleic acid in situ hybridization analysis of estrogen receptors α and β in human breast carcinoma. J Clin Endocrinol Meta 84: 781-785 (1999).
36. Tanimoto K, Eguchi H, Yoshida T, Hajiro-Nakanishi K, Hayashi S-I: Regulation of estrogen receptor α gene mediated by promoter B responsible for its enhanced expression in human breast cancer. Nucleic Acids Res 27: 903-909 (1999).
37. Tateishi Y, Kawabe YI, Chiba T, Murata S, Ichikawa K, Murayama A, Tanaka K, Baba T, Kato S, Yanagisawa J: Ligand-dependent switching of ubiquitin-proteasome pathways for estrogen receptor. EMBO J 23: 4813-4823 (2004).
38. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S: Hypermethylation of 14-3-3σ(stratifin) is an early event in breast cancer. Oncogene 20: 3348-3353 (2001).
39. Urano T, Saito T, Tsukui T, Fujita M, Hosoi T, Muramatsu M, Ouchi Y, Inoue S: Efp targets 14-3-3σ for proteolysis and promotes breast tumour growth. Nature 417: 871-875 (2002).
40. Vercoutter-Edouart AS, Lemoine J, Le Bourhis X, Louis H, Boilly B, Nurcombe V, Revillion F, Peyrat JP, Hondermarck H: Proteomic analysis reveals that 14-3-3σ is down-regulated in human breast cancer cells. Cancer Res 61: 76-80 (2001).
41. Watanabe T, Inoue S, Hiroi H, Orimo A, Kawashima H, Muramatsu M: Isolation of estrogen-responsive genes with a CpG island library. Mol Cell Biol 18: 442-449 (1998).
42. Wiseman LR, Adkins JC: Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer. Drugs Aging 13: 321-332 (1998).